Marc N. Casper - 02 Nov 2023 Form 4 Insider Report for THERMO FISHER SCIENTIFIC INC. (TMO)

Role
Chairman & CEO, Director
Signature
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper
Issuer symbol
TMO
Transactions as of
02 Nov 2023
Net transactions value
-$5,862,739
Form type
4
Filing time
06 Nov 2023, 16:34:20 UTC
Previous filing
29 Aug 2023
Next filing
08 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMO Common Stock Options Exercise $1,576,800 +10,000 +7.6% $157.68 141,175 02 Nov 2023 Direct
transaction TMO Common Stock Sale $487,124 -1,100 -0.78% $442.84 140,075 02 Nov 2023 Direct F1, F2
transaction TMO Common Stock Sale $841,089 -1,892 -1.4% $444.55 138,183 02 Nov 2023 Direct F1, F3
transaction TMO Common Stock Sale $1,646,122 -3,695 -2.7% $445.50 134,488 02 Nov 2023 Direct F1, F4
transaction TMO Common Stock Sale $937,776 -2,100 -1.6% $446.56 132,388 02 Nov 2023 Direct F1, F5
transaction TMO Common Stock Sale $542,769 -1,213 -0.92% $447.46 131,175 02 Nov 2023 Direct F1, F6
transaction TMO Common Stock Options Exercise $1,576,800 +10,000 +7.6% $157.68 141,175 03 Nov 2023 Direct
transaction TMO Common Stock Sale $90,694 -200 -0.14% $453.47 140,975 03 Nov 2023 Direct F1, F7
transaction TMO Common Stock Sale $1,135,361 -2,497 -1.8% $454.69 138,478 03 Nov 2023 Direct F1, F8
transaction TMO Common Stock Sale $1,516,726 -3,329 -2.4% $455.61 135,149 03 Nov 2023 Direct F1, F9
transaction TMO Common Stock Sale $517,750 -1,134 -0.84% $456.57 134,015 03 Nov 2023 Direct F1, F10
transaction TMO Common Stock Sale $842,058 -1,840 -1.4% $457.64 132,175 03 Nov 2023 Direct F1, F11
transaction TMO Common Stock Sale $366,864 -800 -0.61% $458.58 131,375 03 Nov 2023 Direct F1, F12
transaction TMO Common Stock Sale $92,006 -200 -0.15% $460.03 131,175 03 Nov 2023 Direct F1, F13
holding TMO Common Stock 5,300 02 Nov 2023 By Alison Casper 2020 Irrevocable Trust F14
holding TMO Common Stock 59,155 02 Nov 2023 By Floral Park Associates, Inc.
holding TMO Common Stock 5,000 02 Nov 2023 By MNC 2020 Irrevocable Trust F15
holding TMO Common Stock 6,000 02 Nov 2023 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMO Stock Option (Right to Buy) Options Exercise $0 -10,000 -32% $0.000000 21,600 02 Nov 2023 Common Stock 10,000 $157.68 Direct F16
transaction TMO Stock Option (Right to Buy) Options Exercise $0 -10,000 -46% $0.000000 11,600 03 Nov 2023 Common Stock 10,000 $157.68 Direct F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $442.27 to $443.19, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $444.00 to $444.79, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $445.06 to $446.04, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $446.12 to $446.93, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $447.135 to $448.00, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $453.30 to $453.64, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $454.06 to $455.05, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $455.08 to $456.05, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $456.10 to $457.06, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $457.26 to $458.22, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $458.31 to $459.16, inclusive.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $459.77 to $460.28, inclusive.
F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F16 The option vested in four equal installments on February 28, 2018, 2019, 2020, and 2021.